Basal cell carcinoma: Hedgehog pathway inhibitors and beyond

Cutis

Volumn 91, Issue 6, 2013, Pages

  Walls, Brooke ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILIDE; PYRIDINE DERIVATIVE; SONIC HEDGEHOG PROTEIN; VISMODEGIB;

ARTICLE; BASAL CELL CARCINOMA; DRUG ANTAGONISM; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN TUMOR;

ANILIDES; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; PYRIDINES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84882290190     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Snow SN, Sahl W, Lo JS, et al. Metastatic basal cell carcinoma. report of !ve cases. Cancer. 1994;73:328-335.
2. Paver K, Poyzer K, Burry N, et al. Letter: the incidence of basal cell carcinoma and their metastases in Australia and New Zealand. Australas J Dermatol. 1973;14:53.
3. Weedon D, Wall D. Metastatic basal cell carcinoma. Med J Aust. 1975;2:177-179.
4. Hahn H, Wicking C, Zaphiropoulous FG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85: 841-851.
5. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668-1671.
6. Vismodegib granted FDA approval for treatment of basal cell carcinoma. Oncology (Williston Park). 2012;26: 174, 213.
7. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980;287:795-801.
8. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22:2454-2472.
9. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743-754.
10. Gailani MR, Stahle-Bäckdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14:78-81.
11. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998;391:90-92.
12. Beach DF, Somer R. Novel approach to Gorlin Syndrome: a patient treated with oral capecitabine [published online ahead of print February 28, 2011]. J Clin Oncol. 2011;29:e397-e401.
13. Binus W, Shupe JL, Keeler RF, et al. Chronologic evaluation of teratogenicity in sheep fed Veratrum californicum. J Am Vet Med Assoc. 1965;147:839-842.
14. Bryden MM, Evans HE, Keeler RF. Cyclopia in sheep caused by plant teratogens. J Anat. 1971;110(pt 3):507.
15. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature. 2000;406:1005-1009.
16. Chen JK, Taipale J, Young KE, et al. Small molecule modulation of smoothened activity [published online ahead of print October 21, 2002]. Proc Natl Acad Sci. 2002;99:14071-14076.
17. Chen JK, Taipale J, Cooper MK, et al. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 2002;16:2743-2748.
18. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma [published online ahead of print September 2, 2009]. N Engl J Med. 2009;361:1164-1172.
19. Sekulic A, Migden MR, Oro AE, et al. Ef!cacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-2179.
20. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366: 2180-2188.
21. Wolfe CM, Green WH, Cognetta AB Jr, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient [published online ahead of print July 17, 2012]. Dermatol Surg. 2012;38:1833-1836.
22. Kimura H, Ng JM, Curran T. Transient inhibition of the hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell. 2008;13:249-260.
23. Vismodegib in treating patients with basal cell carcinoma. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov /ct2/show/study/NCT01631331?term!Vismodegib+in+Treating+Patients+With+Basal+Cell+Carcinoma&rank=1. Received June 22, 2012. Updated February 14, 2013. Accessed June 7, 2013.
24. A study evaluating the ef=cacy and safety of vismodegib (GDC-0449) in operable basal cell carcinoma (BCC). ClinicalTrials.gov Web site. http://www.clinicaltrials .gov/ct2/show/NCT01201915?term=A+Study+Evaluating+the+Efficacy+and+Safety+of+Vismodegib&rank=2. Received September 10, 2010. Updated April 5 2013. Accessed June 7, 2013.
25. Trial comparing the effects of intermittent vismodegib versus photodynamic therapy in patients with multiple basal cell carcinomas. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT01556009?term=Trial+Comparing+the+Effects+of+Intermittent+Vismodegib+Versus+Photodynamic+Therapy+in+Patients+With+Multiple+Basal+Cell+Carcinomas&rank=1. Received March 14, 2012. Updated February 19, 2013. Accessed June 7, 2013.
26. Tang T, Tang JY, Li D, et al. Targeting super=cial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened [published May 10, 2011]. Clin Cancer Res. 2011;17:3378-3387.
27. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor [published online ahead of print March 24, 2011. J Invest Dermatol. 2011;131:1735-1744.
28. Diaz LA Jr, Williams RT, Wu J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486:537-540.
29. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536.
30. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma [published online ahead of print September 2, 2009]. Science. 2009;326: 572-574.
31. Wang Y, Ding Q, Yen CJ, et al. The crosstalk of mTOR/S6K1 and hedgehog pathways. Cancer Cell. 2012;21:374-387.
32. Lauth M, Bergström A, Shimokawa T, et al. Inhibition of the GLI-mediated transcription and tumor cell growth by small-molecule antagonists [published online ahead of print May 9, 2007]. Proc Natl Acad Sci U S A. 2007;104:8455-8460.
33. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists [published online ahead of print January 3, 2013]. Cancer Cell. 2013;23:23-34.
34. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17:388-399.